Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.625 | 4.00% | 16.25 | 1,844,068 | 13:13:51 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 16.00 | 16.50 | 16.25 | 15.625 | 15.625 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0125 | -13.00 | 35.33M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 17:05:42 | O | 450,000 | 15.70 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 19/11/2024 | 07:00 | UK RNS | SkinBioTherapeutics PLC Finalisation of commercial agreement with Croda |
| 25/10/2024 | 15:29 | UK RNS | SkinBioTherapeutics PLC Holding(s) in Company |
| 23/10/2024 | 15:34 | ALNC |  IN BRIEF: SkinBioTherapeutics boosts financial 2025 turnover forecast |
| 23/10/2024 | 13:40 | UK RNS | SkinBioTherapeutics PLC Integration update and share price movement |
| 17/10/2024 | 06:00 | UK RNS | SkinBioTherapeutics PLC Holding(s) in Company |
| 16/10/2024 | 06:00 | UK RNS | SkinBioTherapeutics PLC Issue of Equity and Total Voting Rights |
| 11/10/2024 | 06:00 | UK RNS | SkinBioTherapeutics PLC Acquisition and Financial Update |
| 04/10/2024 | 13:02 | UK RNS | SkinBioTherapeutics PLC Notice of Investor Meet Company Presentation |
| 19/9/2024 | 06:00 | UK RNS | SkinBioTherapeutics PLC Final testing of SkinBiotix by Croda completed |
| 13/8/2024 | 11:49 | UK RNS | SkinBioTherapeutics PLC Holding(s) in Company |
Skinbiotherapeutics (SBTX) Share Charts1 Year Skinbiotherapeutics Chart |
|
1 Month Skinbiotherapeutics Chart |
Intraday Skinbiotherapeutics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 20/11/2024 | 23:15 | SkinBioTherapeutics PLC | 6,377 |
| 20/11/2024 | 21:38 | SkinBioTherapeutics PLC - Multi $bn skin health opportunities. | 20,490 |
| 22/10/2024 | 18:33 | The new Matrixyl set to revolutionise skin care | 100 |
| 23/9/2024 | 15:08 | Sbtx going forward | 5 |
| 16/6/2024 | 11:21 | Senti-mentalRiles - Joseph Sheedy | 195 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-11-20 17:15:00 | 15.70 | 450,000 | 70,650.00 | O |
| 2024-11-20 17:05:43 | 16.25 | 20,000 | 3,250.00 | O |
| 2024-11-20 16:22:29 | 16.03 | 1,500 | 240.41 | O |
| 2024-11-20 16:19:15 | 16.28 | 5,000 | 814.00 | O |
| 2024-11-20 15:24:12 | 16.30 | 12,085 | 1,969.86 | O |
| Top Posts |
|---|
Posted at 20/11/2024 08:20 by Skinbiotherapeutics Daily Update Skinbiotherapeutics Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker SBTX. The last closing price for Skinbiotherapeutics was 15.63p.Skinbiotherapeutics currently has 226,086,285 shares in issue. The market capitalisation of Skinbiotherapeutics is £36,739,021. Skinbiotherapeutics has a price to earnings ratio (PE ratio) of -13.00. This morning SBTX shares opened at 15.63p |
Posted at 18/11/2024 15:45 by cielos British BullsFriday's at close confirmation to buy at 13.81p >>>>> SBTX 13.75 Market Outlook The last pattern detected was bullish with positive implications. The overall evidence, however, is saying “Watch Out!” but it is not yet pointing to BUY. The share price is still not above the confirmation level and the signal is suggesting to STAY IN CASH, but the chance of a bullish confirmation that will change the signal to BUY is quite high |
Posted at 11/11/2024 22:42 by master rsi Why it was a better Buys day, but NO movement in share price?Do not look at the ADVFN trades as they do not adequately correspond as most buys were at below middle price due to the large spread. Spread 14.25 v 15p Today buys started at 14.58p, then 14.60 and 14.75p at the end. Sales 14.25p then 14.3778 and at close at 14.41p total volume 259,673 buys 235,780 sales 23,893 |
Posted at 28/10/2024 21:48 by kreature Sold a few due to 100k chunks getting creamed offWas there another ‘Share Price Movement’ RNS ? ‘we know of no reason for the rise’ ? lol Or are they not bothered if the share price follows a script ? |
Posted at 25/10/2024 17:14 by putinaire OPTI is a good look into what the coming years are for sbtxSimply more PI mincing at lower share price Not much else |
Posted at 24/10/2024 08:42 by putinaire OPTI RNS recently, included advice to PBX[... OptiBiotix advised of its recent successful fundraise of £1.35m by the Company and identified lack of market communication by Mr Andersen as the main reason for the failed PBX fundraise. OptiBiotix requested that PBX increase its news flow to potentially support the share price and build positive investor sentiment ...] Did they advise SBTX yesterday too? So more could be sold? |
Posted at 23/10/2024 18:45 by kreature RNS Translation‘No reason for share price movement’ Translation: What is going on ? ‘ No rationale for share price movement ‘ Translation: We don’t understand, we have no clue, help ‘ to the Board's knowledge, there is no reason behind it.’ Translation: ‘We don’t understand that more selling pressure than buying, can be a reason for a share price to be marked lower ‘ Imo |
Posted at 23/10/2024 18:25 by kreature ‘ No rationale for share price movement ‘For balance, I’d say the rational could be…. 1. Profit taking following a 50% share price rise 2. Uncertainty concerning the Opti situation 3. Investors understanding that turnover is not net profit 4. Just a general sense of binaryness in the air. In my opinion, as always. |
Posted at 23/10/2024 18:15 by kreature RNS sub titles looks a bit desperate given stated twice below, imv tbf. In fairness, I bet some systems just don’t work unless the share price remains within a distribution zone ? Also tbf turnover is not earnings right ?‘No reason for share price movement’ ‘No rationale for share price movement ‘ |
Posted at 21/10/2024 16:56 by theterrier DYORStuart J. Ashman (CEO) In post 5.5yrs. Remuneration £382,480 - £306,000 (2023, 20% reduction 2024). Total from appointment approx. £1,800,000+/-. Shares purchased: 125,000 (2020) paid £0.16 per share (total £20,000), 156,250 (2022) paid £0.16 per share (total £25,000). Number of shares held 276,804. Invested in company £45,000. % holding: 0.121%. Options held 5,189,444 at exercise price of £0.09 and £0.18. Manprit Randhawa (CFO) In post 2.3yrs. Remuneration £261,480 - £209,100 (2023, 20% reduction 2024). Total Remuneration from appointment approx. £500,000+/-. Shares purchased: 156,250 (2022) paid £0.16 per share (total £25,000). Number of shares held 153,165. % holding: 0.067%. Invested in company £25,000. Martin Hunt (Non-Executive Chairman) In post 8yrs. Remuneration/fees £68,670 (2023). Remuneration/fees from appointment £460,000+/-. Shares held 466,667 (2018): Buy 93,750 (2022) paid £0.16 per share (total £15,000). Number of shares held 560,417. Invested in company £15,000. % holding: 0.245%. Options held 3,892,082 at exercise price of £0.09. Cathy Prescott (Non-Executive Director) In post 7.6yrs. Remuneration/fees £41,011 (2023). Remuneration/fees from appointment £215,000+/-. Shares purchased: 56,112 (2019) paid £0.1782 (total £10,000): 62,500 (2020) paid £0.16 per share (total £10,000). 62,500 (2022) paid £0.16 per share (Total £10,000). Number of shares held 181,112. Invested in company £30,000. % holding: 0.079%. Danielle Bekker (Non-Executive Director) In post 2.5yrs. Remuneration/fees £25,000 (2023). Remuneration from appointment £56,250+/-. Shares purchased: 43,750 (2022) paid £0.16 per share (total £7,000). Invested in company £7,000. % holding: 0.019%. |
Posted at 15/10/2024 09:44 by cowickhaller All playing out exactly as I thought.Great that SBTX now have a ‘Croda insider’ on board, that will level things up somewhat. There were things in the podcast that have not really been picked up on. A few examples. SBTX & Croda are planning further collaborations. This ties SBTX in further with Croda and together they could be a real powerhouse in their chosen field. SA talked about Matrixyl and replacing it. SA has to be careful with what he says, understandably so, but listen to the mood music and watch the body language. Finally SA talks about not resting till the SBTX share price is over £1. I fully endorse his conservatism. If this takes off as expected, we are certainly talking multiples of that. With the CRDA share price bouncing around the lows, CRDA need this development to succeed and it will. It’s not often industrial chemical companies like CRDA make the news, unless it’s for the wrong reasons. I predict it will happen here for the right reasons, April 2025. A blink of an eye for seasoned investors but a lifetime for some. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
